Therapy Areas: AIDS & HIV
Astria Therapeutics Presents New Preclinical Data Showing Differentiated Profile of STAR-0215, in Development for Treatment of Hereditary Angioedema
5 July 2022 - - US-based biopharmaceutical company Astria Therapeutics, Inc. (NASDAQ: ATXS) has presented new preclinical data that demonstrate STAR-0215's rapid and durable inhibition of plasma kallikrein in cynomolgus monkeys, supporting the potential for once every three month or longer dosing in humans, the company said.

The Flash Talks session entitled "STAR-0215, a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor in Development for Treatment of HAE, Demonstrated Sustained Functional Inhibition in Subcutaneously Dosed Cynomolgus Monkeys" was presented at the European Academy of Allergy and Immunology 2022 Hybrid Congress in Prague, Czech Republic.

The study, conducted in cynomolgus monkeys, showed rapid inhibition of plasma kallikrein after subcutaneous administration.

Inhibition of HMWK cleavage was rapid and sustained throughout an 84-day dose-free period in the extended portion of the study.

These data confirm the long half-life of STAR-0215 and demonstrate prolonged pharmacological activity of STAR-0215 in circulation in cynomolgus monkeys.

STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein designed to provide long-acting, effective attack prevention for HAE with dosing once every three months or longer. The company's goal is to provide the most patient-friendly preventative treatment option for people living with HAE.

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases.

Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.


Related Headlines